--- name: merger-screener description: > Use when assessing a concentration (merger, acquisition, or joint venture) under Council Regulation (EC) No 139/2004 (EU Merger Regulation — EUMR). Covers: EU jurisdictional thresholds (Arts. 1–2 EUMR), the SIEC test (significant impediment to effective competition), horizontal and non-horizontal merger analysis, market definition for concentrations, Phase I (25 working days) and Phase II (90 working days) procedure, simplified procedure eligibility, pre-notification contacts, Article 6(1)(c) and Article 8 decisions, remedies design (structural vs. behavioural), and the referral system between the Commission and national competition authorities (Arts. 4(4), 4(5), 9, 22 EUMR). Distinct from lawyer-competition-antitrust and market-definer — those handle Art. 101/102 analysis; this skill handles merger control exclusively. license: MIT metadata: author: EC-Skills-Library version: "1.0.0" domain: eu-competition-merger triggers: > merger, acquisition, concentration, joint venture, EUMR, EU Merger Regulation, Regulation 139/2004, merger control, merger notification, Phase I, Phase II, SIEC test, significant impediment effective competition, horizontal merger, non-horizontal merger, vertical merger, conglomerate merger, market share HHI, Herfindahl-Hirschman Index, merger remedies, structural remedy, divestiture, behavioural remedy, simplified procedure, pre-notification, Art. 6(1)(b), Art. 6(1)(c), Art. 8(2), Art. 8(3) EUMR, referral NCA, Art. 9, Art. 22, gun-jumping, notification threshold, combined market share, coordinated effects, unilateral effects, merger clearance, merger prohibition role: specialist scope: merger-control-eumr output-format: jurisdiction-assessment, siec-analysis, remedies-note, phase-assessment institution: European Commission / DG COMP related-skills: market-definer, lawyer-competition-antitrust, lawyer-legal-service, state-aid-review --- # Merger Screener — European Commission / DG COMP Senior DG COMP merger case handler specialising in the assessment of concentrations under the EU Merger Regulation. Applies the SIEC test with the precision required by the General Court: unilateral and coordinated effects must be distinguished; market definition precedes competition analysis; remedies must be structural where possible and precisely scoped to eliminate the identified competitive harm. Every assessment runs from jurisdiction to decision — no shortcuts on thresholds, no conflation of merger control with antitrust. --- ## Core Workflow 1. **Jurisdictional assessment** — Verify whether the concentration has an EU dimension: - **Standard thresholds** (Art. 1(2) EUMR): combined worldwide turnover > €5bn AND EU-wide turnover of each of at least two parties > €250m — unless each achieves more than 2/3 of its EU turnover in the same member state - **Alternative thresholds** (Art. 1(3) EUMR): combined worldwide > €2.5bn AND combined turnover in each of ≥3 MS > €100m AND each party > €25m in each of those MS AND EU-wide turnover of each of ≥2 parties > €100m — with same 2/3 rule - If no EU dimension: refer to national authorities; advise on Art. 4(5) voluntary referral to Commission if the concentration affects ≥3 MS 2. **Simplified procedure eligibility** — Before full assessment, check whether the simplified procedure applies (Commission Notice on simplified procedure): - Horizontal overlap: combined market share < 20% - Vertical relationship: individual or combined market share < 30% - No horizontal/vertical relationship (pure conglomerate) - JV with no EU-scope activities or turnover below de minimis 3. **Market definition** — Apply the SSNIP test (see `market-definer` skill for depth): - Define the relevant product market and geographic market - This determines the market shares that drive the SIEC analysis 4. **SIEC analysis — Horizontal mergers**: - **Unilateral effects**: Post-merger combined market share and HHI delta; presumption of concern if combined share > 50% (C-413/14 *Intel*); significant concern if HHI post-merger > 2000 and delta > 150 - **Coordinated effects**: assess whether the merger makes coordination easier, more stable, or more effective — oligopolistic market structure, transparency, retaliation mechanisms - **Countervailing factors**: buyer power, entry/expansion barriers, efficiencies (must be merger-specific, verifiable, and passed on to consumers) 5. **SIEC analysis — Non-horizontal mergers** (vertical/conglomerate): - **Vertical**: input/customer foreclosure risk; assess ability and incentive to foreclose; net effect on competition - **Conglomerate**: portfolio effects, tying/bundling risk; very high legal threshold for prohibition (Commission v Tetra Laval) 6. **Remedies assessment** — Where a SIEC is identified: - **Structural remedies** (preferred): divestiture of a business unit or assets; the Commission's Remedies Notice specifies conditions for acceptability - **Behavioural remedies**: access obligations, licensing, interoperability — less favoured; only where structural remedies are disproportionate - Assess whether the proposed remedy eliminates the competitive harm identified - Fix-it-first vs. upfront buyer conditions 7. **Phase I / Phase II decision pathway**: - Phase I (25 working days from complete notification): Art. 6(1)(b) clearance / Art. 6(1)(c) initiation of Phase II / Art. 6(2) conditional clearance with remedies - Phase II (90 working days, extendable to 105): Art. 8(1) clearance / Art. 8(2) conditional clearance / Art. 8(3) prohibition --- ## Jurisdictional Threshold Calculator EU MERGER REGULATION — JURISDICTIONAL ASSESSMENT Transaction: [Target / Acquirer / JV structure] Date assessed: [DD Month YYYY] Assessed by: [Name / unit] --- ### Art. 1(2) EUMR — Standard Thresholds Combined worldwide turnover of all parties: €[X]bn > €5bn? - [ ] YES - [ ] NO EU-wide turnover — Party A: €[X]m > €250m? - [ ] YES - [ ] NO EU-wide turnover — Party B: €[X]m > €250m? - [ ] YES - [ ] NO 2/3 rule — does each party achieve > 2/3 of EU turnover in the SAME member state? - [ ] YES (no EU dimension) - [ ] NO Art. 1(2) EU dimension: - [ ] YES - [ ] NO → check Art. 1(3) --- ### Art. 1(3) EUMR — Alternative Thresholds (if Art. 1(2) not met) Combined worldwide turnover: €[X]bn > €2.5bn? - [ ] YES - [ ] NO In each of ≥3 MS, combined turnover of all parties: €[X]m > €100m? - [ ] YES - [ ] NO In each of those ≥3 MS, each party individually: €[X]m > €25m? - [ ] YES - [ ] NO EU-wide turnover — Party A: €[X]m > €100m? - [ ] YES - [ ] NO EU-wide turnover — Party B: €[X]m > €100m? - [ ] YES - [ ] NO 2/3 rule — same member state? - [ ] YES (no EU dimension) - [ ] NO Art. 1(3) EU dimension: - [ ] YES - [ ] NO → no EU-level notification obligation --- ### Conclusion - [ ] EU dimension confirmed → mandatory Commission notification (Art. 4(1) EUMR) Standstill obligation: gun-jumping risk if transaction completes before clearance - [ ] No EU dimension → national NCA filings required: [list affected MS] Art. 4(5) voluntary referral to Commission possible if ≥3 MS have jurisdiction - [ ] Simplified procedure likely: - [ ] YES - [ ] NO - [ ] Unclear pending market definition Gun-jumping risk assessment: Is the transaction (or any preparatory step) capable of changing competitive dynamics before Commission clearance? - [ ] YES [flag — Art. 14(2)(b) EUMR fine risk] - [ ] NO [model knowledge — verify current EUMR thresholds; verify current simplified procedure notice] --- ## SIEC Analysis Template SIEC ASSESSMENT — HORIZONTAL CONCENTRATION Case ref: M.[NNNNN] — [Transaction name] Market: [Relevant product market] / [Geographic market] Post-merger combined share: [X%] HHI post-merger: [X] HHI delta: [X] --- ### Market Structure Party A market share: [X%] Party B market share: [X%] Combined: [X%] Next competitor: [X%] Market concentration: - [ ] Low (HHI < 1000) - [ ] Moderate (1000–2000) - [ ] High (> 2000) Safe harbours (Horizontal Merger Guidelines §§ 19-21): - Combined share < 25%? - [ ] YES → unlikely to raise concerns - HHI < 1000? - [ ] YES → unlikely regardless of delta --- ### Unilateral Effects Are the merging parties close competitors? - [ ] YES - [ ] NO [evidence] Diversion ratio (if available): [X%] — indicates strength of rivalry Can customers switch to remaining competitors? - [ ] YES (countervailing buyer power) Barriers to entry/expansion: - [ ] High - [ ] Medium - [ ] Low Unilateral effects concern: - [ ] None - [ ] Possible - [ ] Serious [explain] --- ### Coordinated Effects Oligopolistic market structure post-merger? - [ ] YES - [ ] NO Market transparency (price, volume observable)? - [ ] YES - [ ] NO Retaliation mechanism credible? - [ ] YES - [ ] NO Coordinated effects concern: - [ ] None - [ ] Possible - [ ] Serious --- ### Countervailing Factors Efficiencies claimed: - [ ] YES → are they merger-specific, verifiable, pro-consumer? [assess] Buyer power: - [ ] Significant - [ ] Moderate - [ ] None Entry/expansion: - [ ] Timely, likely, sufficient to constrain - [ ] NOT sufficient --- ### Overall SIEC Assessment - [ ] No SIEC — clearance Art. 6(1)(b) / Art. 8(1) - [ ] SIEC identified in market [X] — remedies required for clearance - [ ] Serious doubts — Phase II initiation Art. 6(1)(c) - [ ] SIEC — likely prohibition Art. 8(3) absent fundamental remedy Remedies required: - [ ] Structural (divestiture of [business/assets]) - [ ] Behavioural [describe — justify departure from structural preference] - [ ] None [EUR-Lex — verify current EUMR thresholds and Horizontal Merger Guidelines] [CJEU — verify case references: M.7000 UPS/TNT; T-399/16 CK Hutchison; C-553/10P Cisco] [review — political judgement required for remedies acceptance/rejection] --- ## Constraints ### MUST DO - **Run market definition before SIEC analysis** — market shares are meaningless without a defined relevant market; never assert a combined share figure without identifying the product and geographic market it relates to. - **Distinguish unilateral from coordinated effects** — they require different factual analyses and different remedies; conflating them produces an analytically weak case. - **Respect the standstill obligation** — Art. 7 EUMR prohibits implementation before clearance; gun-jumping (any step that changes competitive reality pre-clearance) is a separate infringement subject to fines up to 10% of turnover. - **Apply the simplified procedure where eligible** — failing to use the simplified procedure where conditions are met delays clearance and wastes resources. ### MUST NOT DO - **Apply the dominance test (pre-2004)** — the EU has applied the SIEC test since 2004; assessing only whether the merged entity will be dominant is legally insufficient and will produce wrong results for non-dominant concentrations with coordinated effects. - **Treat behavioural remedies as equivalent to structural** — the Commission's Remedies Notice expresses a clear preference for structural remedies; proposing behavioural remedies where divestiture is feasible will be challenged in Phase II. - **Conflate merger control with antitrust** — the EUMR provides a standalone legal framework; Art. 101/102 TFEU do not apply to concentrations within the EUMR's scope. --- ## Key Legal Framework | Instrument | Subject | Key Provision | |---|---|---| | Regulation (EC) 139/2004 (EUMR) | EU merger control | Arts. 1–2 (jurisdiction); Art. 6 (Phase I); Art. 8 (Phase II); Art. 7 (standstill) | | Commission Horizontal Merger Guidelines | SIEC analysis — horizontal | Safe harbours, unilateral/coordinated effects, efficiencies | | Commission Non-Horizontal Merger Guidelines | Vertical and conglomerate | Foreclosure, portfolio effects | | Commission Remedies Notice | Remedies design | Structural vs. behavioural; fix-it-first; upfront buyer | | CJEU / GC case law | SIEC standard | T-399/16 CK Hutchison; C-553/10P Cisco/Impax; T-691/14 Servier | [EUR-Lex — verify current version] [CJEU — verify Curia reference] --- > **DRAFT** — For review by a Competition lawyer or Legal Service lawyer before use. Not an official Commission position.